Logo do repositório

Peptide Dimerization as a Strategy for the Development of Antileishmanial Compounds

dc.contributor.authorCoelho, Natália C. S. [UNESP]
dc.contributor.authorPortuondo, Deivys L. F. [UNESP]
dc.contributor.authorLima, Jhonatan [UNESP]
dc.contributor.authorVelásquez, Angela M. A. [UNESP]
dc.contributor.authorValente, Valéria [UNESP]
dc.contributor.authorCarlos, Iracilda Z. [UNESP]
dc.contributor.authorCilli, Eduardo M. [UNESP]
dc.contributor.authorGraminha, Márcia A. S. [UNESP]
dc.contributor.institutionUniversidade Estadual Paulista (UNESP)
dc.date.accessioned2025-04-29T19:15:23Z
dc.date.issued2024-11-01
dc.description.abstractLeishmaniasis is recognized as a serious public health problem in Brazil and around the world. The limited availability of drugs for treatment, added to the diversity of side effects and the emergence of resistant strains, shows the importance of research focused on the development of new molecules, thus contributing to treatments. Therefore, this work aimed to identify leishmanicidal compounds using a peptide dimerization strategy, as well as to understand their mechanisms of action. Herein, it was demonstrated that the dimerization of the peptide TSHa, (TSHa)2K, presented higher potency and selectivity than its monomeric form when evaluated against Leishmania mexicana and Leishmania amazonensis. Furthermore, these compounds are capable of inhibiting the parasite cysteine protease, an important target explored for the development of antileishmanial compounds, as well as to selectively interact with the parasite membranes, as demonstrated by flow cytometry, permeabilization, and fluorescence microscopy experiments. Based on this, the identified molecules are candidates for use in in vivo studies with animal models to combat leishmaniasis.en
dc.description.affiliationDepartment of Clinical Analysis School of Pharmaceutical Sciences São Paulo State University (UNESP), SP
dc.description.affiliationDepartment of Biochemistry and Organic Chemistry Institute of Chemistry São Paulo State University (UNESP), SP
dc.description.affiliationUnespDepartment of Clinical Analysis School of Pharmaceutical Sciences São Paulo State University (UNESP), SP
dc.description.affiliationUnespDepartment of Biochemistry and Organic Chemistry Institute of Chemistry São Paulo State University (UNESP), SP
dc.description.sponsorshipFundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP)
dc.description.sponsorshipIdFAPESP: 20/04415-4
dc.description.sponsorshipIdFAPESP: 2013/07600-3
dc.description.sponsorshipIdFAPESP: 22/05411-8
dc.identifierhttp://dx.doi.org/10.3390/molecules29215170
dc.identifier.citationMolecules, v. 29, n. 21, 2024.
dc.identifier.doi10.3390/molecules29215170
dc.identifier.issn1420-3049
dc.identifier.scopus2-s2.0-85208549812
dc.identifier.urihttps://hdl.handle.net/11449/302712
dc.language.isoeng
dc.relation.ispartofMolecules
dc.sourceScopus
dc.subjectantimicrobial peptides
dc.subjectdimerization
dc.subjectLeishmania
dc.subjectmembrane
dc.subjecttemporin
dc.subjectTSHa
dc.titlePeptide Dimerization as a Strategy for the Development of Antileishmanial Compoundsen
dc.typeArtigopt
dspace.entity.typePublication
relation.isOrgUnitOfPublication95697b0b-8977-4af6-88d5-c29c80b5ee92
relation.isOrgUnitOfPublicationbc74a1ce-4c4c-4dad-8378-83962d76c4fd
relation.isOrgUnitOfPublication.latestForDiscovery95697b0b-8977-4af6-88d5-c29c80b5ee92
unesp.author.orcid0000-0002-7250-4908[1]
unesp.author.orcid0000-0003-2678-0431[2]
unesp.author.orcid0000-0002-4709-5487[3]
unesp.author.orcid0000-0002-0084-3468[6]
unesp.author.orcid0000-0002-4767-0904[7]
unesp.author.orcid0000-0001-7280-3775[8]
unesp.campusUniversidade Estadual Paulista (UNESP), Faculdade de Ciências Farmacêuticas, Araraquarapt
unesp.campusUniversidade Estadual Paulista (UNESP), Instituto de Química, Araraquarapt

Arquivos